Triptorelin Acetate PR 1-month

Phase 3Small molecule

Triptorelin Acetate PR 1-month is one of 37 small molecule programs targeting Endometriosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndometriosisActive, not recruiting

EndometriosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

199 competitors in Endometriosis

#DrugCompanyPhaseTrials

Revia

Teva

Phase 3

1 2

Lupron

AbbVie

Phase 3

1 3

Lupron

EEastern Cooperative Oncology Group

Phase 3

1 4

Trental

VValidus Pharmaceuticals

Phase 3

1 5

Triptorelin Embonate

Ipsen

Phase 3

1 6

Add-Back

KKissei Pharmaceutical Co., Ltd.

Phase 3

4 7

BG2109

BBio Genuine (Shanghai) Biotech Co., Ltd.

Phase 3

1 8

NPC-01

NNobelpharma

Phase 3

1 9

Depo Medroxyprogesterone Acetate

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

1 10

Cannabidiol Extract

MMilton S. Hershey Medical Center

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Cancer1 trial

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

Completed· Ipsen logo

Ipsen·Phase 3·NCT05590793·195 enrolled

Endometriosis1 trial

Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis

Completed· Ipsen logo

Ipsen·Phase 3·NCT03232281·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Triptorelin Acetate PR 1-month. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triptorelin Acetate PR 1-month compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triptorelin Acetate PR 1-month. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Ipsen

Triptorelin Acetate PR 1-month

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced Cancer1 trial

Endometriosis1 trial

References

Drug Info

Quick Facts

Related News